Takeda’s cancer prospects dim further
After trimming its cell therapy pipeline last year, the group is now out entirely.
Petosemtamab secures a buyout for Merus
Genmab acquires the Dutch biotech for $8bn.
Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Servier eyes up Ideaya’s darovasertib
As pivotal data approach, the French group pays $210m for ex-US rights.
BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
